Agerafenib, also known as RXDX-105, CEP-32496 and AC013773, is an orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. CEP-32496 specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene.
CSF-1R Inhibitors Related Products:
GW2580; Pazopanib; Pazopanib HCl; Linifanib; ENMD-2076; ENMD-2076 Tartrate; OSI-930; Ki20227; PLX5622; Pexidartinib; Pexidartinib HCL; Aprepitant; Erdafitinib; BLZ945